Added to YB: 2026-06-23
Pitch date: 2026-06-20
NOVO-B.CO [neutral]
Novo Nordisk A/S
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.3T
Pitch Price
N/A
Price Target
N/A
Dividend
3.99%
EV/EBITDA
8.10
P/E
10.69
EV/Sales
4.34
Sector
Pharmaceuticals
Category
growth
Show full summary:
The Curious Investor | June 2026 update - Part 1 - Novo Nordisk A/S
NOVO-B.CO (holding update): GLP-1 leader at DKK 295, -11% YTD on weak 2026 guide (sales/op profit -4% to -12%). Wegovy pill strong in US, FDA compounding crackdown a 2027 tailwind. Risks: CagriSema trial miss vs Zepbound, Lilly's retatrutide pipeline. ~7% FCF yield as capex normalizes. 1.5% position.
Read full article (3 min)